Mark J. Rosenblum - 13 Feb 2023 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Exec VP Finance, CFO
Signature
/s/ Mark J. Rosenblum
Issuer symbol
SLRX
Transactions as of
13 Feb 2023
Net transactions value
$0
Form type
4
Filing time
15 Feb 2023, 15:06:23 UTC
Previous filing
05 Jan 2023
Next filing
22 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Award $0 +6,432 +42% $0.000000 21,851 13 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement